Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

the chemours company - CC

CC

Close Chg Chg %
20.76 0.82 3.95%

Closed Market

21.58

+0.82 (3.95%)

Volume: 4.02M

Last Updated:

Mar 26, 2026, 3:59 PM EDT

Trade Now

Company Overview: the chemours company - CC

CC Key Data

Open

$20.26

 Day Range

20.26 - 21.69

52 Week Range

9.13 - 21.85

 Market Cap

$3.12B

Shares Outstanding

150.09M

 Public Float

148.98M

Beta

1.60

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$2.57

Yield

168.51%

 Dividend

$0.09

EX-DIVIDEND DATE

Feb 27, 2026

 SHORT INTEREST

N/A

AVERAGE VOLUME

3.84M

  

CC Performance

1 Week
 
 21.92%
 
1 Month
 
 18.31%
 
3 Months
 
 78.49%
 
1 Year
 
 57.29%
 
5 Years
 
 -21.98%
 

CC Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 12
Full Ratings ➔

About the chemours company - CC

The Chemours Co. is a holding company, which engages in the provision of performance chemicals. The firm delivers solutions, which include a range of industrial and chemical products for markets including coatings, plastics, refrigeration and air conditioning, transportation, semiconductors and consumer electronics, and general industrial. It operates through the following segments: Titanium Technologies, Thermal and Specialized Solutions, Advanced Performance Materials, and Other. The Titanium Technologies segment is involved in the manufacture of titanium dioxide pigment. The Thermal and Specialized Solutions segment offers refrigerants, propellants, blowing agents, and specialty solvents. The Advanced Performance Materials segment produces polymers and advanced materials that deliver attributes, including chemical inertness, thermal stability, low friction, weather and corrosion resistance, extreme temperature stability, and di-electric properties. The Other segment consists of performance chemicals and intermediates business. The company was founded on February 18, 2014 and is headquartered in Wilmington, DE.

CC At a Glance

The Chemours Co.
1007 Market Street
Wilmington, Delaware 19801
Phone 1-302-773-1000 Revenue 5.81B
Industry Chemicals: Specialty Net Income -386,000,000.00
Sector Process Industries 2025 Sales Growth 0.45%
Fiscal Year-end 12 / 2026 Employees 5,700
View SEC Filings

CC Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.305
Price to Book Ratio 7.069
Price to Cash Flow Ratio 6.71
Enterprise Value to EBITDA 8.401
Enterprise Value to Sales 0.946
Total Debt to Enterprise Value 0.80

CC Efficiency

Revenue/Employee 1,018,947.368
Income Per Employee -67,719.298
Receivables Turnover 8.554
Total Asset Turnover 0.78

CC Liquidity

Current Ratio 1.78
Quick Ratio 0.849
Cash Ratio 0.399

CC Profitability

Gross Margin 15.513
Operating Margin 5.406
Pretax Margin -4.769
Net Margin -6.646
Return on Assets -5.182
Return on Equity -90.398
Return on Total Capital -8.312
Return on Invested Capital -8.22

CC Capital Structure

Total Debt to Total Equity 1,757.60
Total Debt to Total Capital 94.617
Total Debt to Total Assets 59.523
Long-Term Debt to Equity 1,716.00
Long-Term Debt to Total Capital 92.377
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for The Chemours Company - CC

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
6.79B 6.03B 5.78B 5.81B
Sales Growth
+7.08% -11.29% -4.07% +0.45%
Cost of Goods Sold (COGS) incl D&A
5.16B 4.72B 4.63B 4.91B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
291.00M 307.00M 301.00M 340.00M
Depreciation
286.00M 297.00M 301.00M 340.00M
Amortization of Intangibles
- - 5.00M 10.00M
-
COGS Growth
+3.97% -8.59% -1.82% +5.98%
Gross Income
1.64B 1.31B 1.15B 901.00M
Gross Income Growth
+18.22% -19.82% -12.13% -21.79%
Gross Profit Margin
+24.07% +21.75% +19.92% +15.51%
2022 2023 2024 2025 5-year trend
SG&A Expense
828.00M 634.00M 694.00M 587.00M
Research & Development
118.00M 108.00M 109.00M 108.00M
Other SG&A
710.00M 526.00M 585.00M 479.00M
SGA Growth
+22.85% -23.43% +9.46% -15.42%
Other Operating Expense
- - - -
-
Unusual Expense
7.00M 925.00M 112.00M 384.00M
EBIT after Unusual Expense
800.00M (248.00M) 346.00M (70.00M)
Non Operating Income/Expense
104.00M 138.00M 45.00M 61.00M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
55.00M 45.00M 43.00M 35.00M
Interest Expense
163.00M 208.00M 264.00M 268.00M
Interest Expense Growth
-11.89% +27.61% +26.92% +1.52%
Gross Interest Expense
170.00M 215.00M 274.00M 274.00M
Interest Capitalized
7.00M 7.00M 10.00M 6.00M
Pretax Income
741.00M (318.00M) 127.00M (277.00M)
Pretax Income Growth
+9.62% -142.91% +139.94% -318.11%
Pretax Margin
+10.91% -5.28% +2.20% -4.77%
Income Tax
163.00M (81.00M) 41.00M 109.00M
Income Tax - Current - Domestic
96.00M 20.00M 6.00M 17.00M
Income Tax - Current - Foreign
47.00M 57.00M 62.00M 32.00M
Income Tax - Deferred - Domestic
6.00M (136.00M) (21.00M) 66.00M
Income Tax - Deferred - Foreign
14.00M (22.00M) (6.00M) (6.00M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
55.00M 45.00M 43.00M 35.00M
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
578.00M (237.00M) 86.00M (386.00M)
Minority Interest Expense
- - - 1.00M
-
Net Income
578.00M (238.00M) 86.00M (386.00M)
Net Income Growth
-4.93% -141.18% +136.13% -548.84%
Net Margin Growth
+8.51% -3.95% +1.49% -6.65%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
578.00M (238.00M) 86.00M (386.00M)
Preferred Dividends
- - - -
-
Net Income Available to Common
578.00M (238.00M) 86.00M (386.00M)
EPS (Basic)
3.7204 -1.5983 0.5753 -2.5693
EPS (Basic) Growth
+0.93% -142.96% +135.99% -546.60%
Basic Shares Outstanding
155.36M 148.91M 149.49M 150.24M
EPS (Diluted)
3.6512 -1.5983 0.5727 -2.5693
EPS (Diluted) Growth
+1.31% -143.77% +135.83% -548.63%
Diluted Shares Outstanding
158.30M 148.91M 150.17M 150.24M
EBITDA
1.10B 984.00M 759.00M 654.00M
EBITDA Growth
+7.02% -10.38% -22.87% -13.83%
EBITDA Margin
+16.16% +16.33% +13.13% +11.26%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 19.30
Number of Ratings 12 Current Quarters Estimate -0.05
FY Report Date 03 / 2026 Current Year's Estimate 1.411
Last Quarter’s Earnings 0.05 Median PE on CY Estimate N/A
Year Ago Earnings 0.95 Next Fiscal Year Estimate 2.236
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 9 9 10 10
Mean Estimate -0.05 0.62 1.41 2.24
High Estimates 0.00 0.73 1.75 2.74
Low Estimate -0.14 0.51 0.93 1.87
Coefficient of Variance -86.69 12.09 16.96 10.90

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 6 6 6
OVERWEIGHT 0 1 1
HOLD 4 4 4
UNDERWEIGHT 2 1 1
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for The Chemours Company - CC

Date Name Shares Transaction Value
Mar 5, 2026 Shane W. Hostetter Chief Financial Officer 54,470 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $18.24 per share 993,532.80
Mar 5, 2026 Shane W. Hostetter Chief Financial Officer 101,857 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 5, 2026 Denise M. Dignam Chief Executive Officer; Director 165,776 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $18.24 per share 3,023,754.24
Mar 5, 2026 Denise M. Dignam Chief Executive Officer; Director 335,314 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 5, 2026 David A. Will Chief Accounting Officer 24,747 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $18.24 per share 451,385.28
Mar 5, 2026 David A. Will Chief Accounting Officer 33,084 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 5, 2026 Kristine M. Wellman SVP, GC & Corp. Secretary 48,043 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $18.24 per share 876,304.32
Mar 5, 2026 Kristine M. Wellman SVP, GC & Corp. Secretary 73,751 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 5, 2026 Calderon Familiar See Remarks 31,584 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $18.24 per share 576,092.16
Mar 5, 2026 Calderon Familiar See Remarks 57,292 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 5, 2026 Joseph T. Martinko See Remarks 25,401 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $18.24 per share 463,314.24
Mar 5, 2026 Joseph T. Martinko See Remarks 53,889 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 5, 2026 Michael Robert Foley See Remarks 28,513 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 5, 2026 Michael Robert Foley See Remarks 78,540 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 7, 2026 Courtney R. Mather Director 6,216 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 7, 2026 Livingston L. Satterthwaite Director 4,615 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

The Chemours Company in the News